Newly emerging therapies for neonatal seizures

Seminars in Fetal and Neonatal Medicine

Volumn 18, Issue 4, 2013, Pages 216-223

  Pressler, Ronit M ^a   Mangum, B ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drug treatment; Bumetanide; Drug trials; Levetiracetam; Newborn; Seizures neonatal; Topiramate

Indexed keywords

BUMETANIDE; ETIRACETAM; FUROSEMIDE; PHENOBARBITAL; TOPIRAMATE;

ADD ON THERAPY; AGE SPECIFIC CARE; AGITATION; ANOREXIA; ANXIETY; APATHY; COGNITIVE DEFECT; DEHYDRATION; DEPERSONALIZATION; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HALF LIFE TIME; HOSTILITY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKINESIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFANTILE SPASM; LOADING DRUG DOSE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NEUROPROTECTION; NEWBORN; NONHUMAN; OTOTOXICITY; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIEPILEPTIC DRUG TREATMENT; BUMETANIDE; DRUG TRIALS; LEVETIRACETAM; NEWBORN; SEIZURES NEONATAL; TOPIRAMATE;

ANIMALS; ANTICONVULSANTS; BRAIN; BUMETANIDE; CHILD DEVELOPMENT; EPILEPSY; FRUCTOSE; HUMANS; INFANT, NEWBORN; NEUROGENESIS; NEURONS; NEUROPROTECTIVE AGENTS; PIRACETAM; SEIZURES; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84880615536     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2013.04.005     Document Type: Review

References (118)

1. Holden K.R., Mellits E.D., Freeman J.M. Neonatal seizures. I. Correlation of prenatal and perinatal events with outcomes. Pediatrics 1982, 70:165-176.
2. McBride M.C., Laroia N., Guillet R. Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology 2000, 55:506-513.
3. Ronen G.M., Buckley D., Penney S., Streiner D.L. Long-term prognosis in children with neonatal seizures: a population-based study. Neurology 2007, 69:1816-1822.
4. Pisani F., Cerminara C., Fusco C., Sisti L. Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome. Neurology 2007, 69:2177-2185.
5. Pisani F., Piccolo B., Cantalupo G., et al. Neonatal seizures and postneonatal epilepsy: a 7-y follow-up study. Pediatr Res 2012, 72:186-193.
6. Glass H.C., Hong K.J., Rogers E.E., et al. Risk factors for epilepsy in children with neonatal encephalopathy. Pediatr Res 2011, 70:535-540.
7. Wirrell E.C., Armstrong E.A., Osman L.D., Yager J.Y. Prolonged seizures exacerbate perinatal hypoxic-ischemic brain damage. Pediatr Res 2001, 50:445-454.
8. Miller S.P., Weiss J., Barnwell A., et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology 2002, 58:542-554.
9. van Rooij L.G., van den Broek M.P., Rademaker C.M., de Vries L.S. Clinical management of seizures in newborns: diagnosis and treatment. Paediatr Drugs 2013, 15:9-18.
10. Glass H.C., Wirrell E. Controversies in neonatal seizure management. JChild Neurol 2009, 24:591-599.
11. Bassan H., Bental Y., Shany E., et al. Neonatal seizures: dilemmas in workup and management. Pediatr Neurol 2008, 38:415-421.
12. Carmo K.B., Barr P. Drug treatment of neonatal seizures by neonatologists and paediatric neurologists. JPaediatr Child Health 2005, 41:313-316.
13. Guillet R., Kwon J.M. Prophylactic phenobarbital administration after resolution of neonatal seizures: survey of current practice. Pediatrics 2008, 122:731-735.
14. Vento M., de Vries L.S., Alberola A., et al. Approach to seizures in the neonatal period: a European perspective. Acta Paediatr 2010, 99:497-501.
15. Silverstein F.S., Ferriero D.M. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008, 39:77-79.
16. World Health Organization Guidelines on neonatal seizures 2011, WHO, Geneva.
17. Booth D., Evans D.J. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004, 4. CD004218.
18. Painter M.J., Scher M.S., Stein A.D., et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. NEngl J Med 1999, 341:485-489.
19. Boylan G.B., Rennie J.M., Chorley G., et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology 2004, 62:486-488.
20. Chiron C., Dulac O., Pons G. Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 2008, 68:17-25.
21. Connock M., Frew E., Evans B.-W., et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Health Technol Assess 2006, 10(7).
22. Weijenberg A., Offringa M., Brouwer O.F., Callenbach P.M. RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology. Epilepsy Res 2010, 91:1-9.
23. Ben-Ari Y. Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci 2008, 31:626-636.
24. Jensen F.E. Neonatal seizures: an update on mechanisms and management. Clin Perinatol 2009, 36:881-900.
25. Donnelly F. EU initiatives for research involving children. Eur J Pediatr 2008, 167:837-838.
26. Aranda J.V., Turmen T., Sasyniuk B.I. Pharmacokinetics of diuretics and methylxanthines in the baby. Eur J Clin Pharmacol 1980, 18:55-63.
27. Ward A., Heel R.C. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984, 28:426-464.
28. Ben Ari Y., Holmes G.L. Effects of seizures on developmental processes in the immature brain. Lancet Neurol 2006, 5:1055-1063.
29. Ben-Ari Y., Gaiarsa J.L., Tyzio R., Khazipov R.G.A.B.A. a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 2007, 87:1215-1284.
30. Dzhala V.I., Talos D.M., Sdrulla D.A., et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005, 11:1205-1213.
31. Glykys J., Dzhala V.I., Kuchibhotla K.V., et al. Differences in cortical versus subcortical GABAergic signaling: a candidate mechanism of electroclinical uncoupling of neonatal seizures. Neuron 2009, 63:657-672.
32. Dzhala V.I., Brumback A.C., Staley K.J. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol 2008, 63:222-235.
33. Sipilä S.T., Schuchmann S., Voipio J., Yamada J., Kaila K. The cation-chloride cotransporter NKCC1 promotes sharp waves in the neonatal rat hippocampus. JPhysiol 2006, 573(Pt 3):765-773.
34. Rheims S., Minlebaev M., Ivanov A., et al. Excitatory GABA in rodent developing neocortex invitro. JNeurophysiol 2008, 100:609-619.
35. Ben-Ari Y., Khalilov I., Kahle K.T., Cherubini E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 2012, 18:467-486.
36. Liu Y., Shangguan Y., Barks J.D., Silverstein F.S. Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model. Pediatr Res 2012, 71:559-565.
37. Cleary R.T., Sun H., Huynh T., et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One 2013, 8:e57148.
38. Marshall J.D., Wells T.G., Letzig L., Kearns G.L. Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. JClin Pharmacol 1998, 38:994-1002.
39. Pacifici G.M. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs 2012, 14:233-246.
40. Sullivan J.E., Witte M.K., Yamashita T.S., Myers C.M., Blumer J.L. Pharmacokinetics of bumetanide in critically ill infants. Clin Pharmacol Ther 1996, 60:405-413.
41. Sullivan J.E., Witte M.K., Yamashita T.S., Myers C.M., Blumer J.L. Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants. Clin Pharmacol Ther 1996, 60:414-423.
42. Lopez-Samblas A.M., Adams J.A., Goldberg R.N., Modi M.W. The pharmacokinetics of bumetanide in the newborn infant. Biol Neonate 1997, 72:265-272.
43. Clark R.H., Bloom B.T., Spitzer A.R., Gerstmann D.R. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117:1979-1987.
44. Turmen T., Thom P., Louridas A.T., LeMorvan P., Aranda J.V. Protein binding and bilirubin displacing properties of bumetanide and furosemide. Clin Pharmacol 1982, 22:551-556.
45. Walker P.C., Shankaran S. The bilirubin-displacing capacity of bumetanide in critically ill babies. Dev Pharmacol Ther 1988, 11:265-272.
46. Henley C. Ototoxicity in developing mammals. Brain Res Rev 1995, 20:68-90.
47. Brummett R.E., Bendrick T., Himes D. Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. JClin Pharmacol 1981, 21:628-636.
48. Prieve B.A., Yanz J.L. Age-dependent changes in susceptibility to ototoxic hearing loss. Acta Otolaryngol 1984, 98:428-438.
49. Tuzel I.H. Comparison of adverse reactions to bumetanide and furosemide. JClin Pharmacol 1981, 21:615-619.
50. Sullivan J.E., Witte M.K., Yamashita T.S., Myers C.M., Blumer J.L. Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants. Clin Pharmacol Ther 1996, 60:424-434.
51. Kumar A., Mittal R., Khanna H.D., Basu S. Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. Pediatrics 2008, 122:e722-e727.
52. Wang D.D., Kriegstein A.R. GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. JNeurosci 2008, 28:5547-5558.
53. Wang D.D., Kriegstein A.R. Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. Cereb Cortex 2011, 21:574-587.
54. - cotransporter NKCC1. JChild Neurol 2009, 24:572-576.
55. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408. Levetiracetam Monotherapy Study Group.
56. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000, 41:1276-1283.
57. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616. N166 Levetiracetam Study Group.
58. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007, 69:1751-1760. Levetiracetam N01057 Study Group.
59. Glauser T.A., Ayala R., Elterman R.D., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660. N159 Study Group.
60. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
61. Margineanu D.G., Klitgaard H. Inhibition of neuronal hypersynchrony invitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000, 42:281-285.
62. Kim J., Kondratyev A., Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. JPharmacol Exp Ther 2007, 323:165-173.
63. Forcelli P.A., Janssen M.J., Vicini S., Gale K. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann Neurol 2012, 72:363-372.
64. Stettner M., Dehmel T., Mausberg A.K., Köhne A., Rose C.R., Kieseier B.C. Levetiracetam exhibits protective properties on rat Schwann cells invitro. Peripher Nerv Syst 2011, 16:250-260.
65. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998, 353:191-206.
66. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43:707-724.
67. Tulloch J.K., Carr R.R., Ensom M.H. Asystematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. JPediatr Pharmacol Ther 2012, 17:31-44.
68. Merhar S.L., Schibler K.R., Sherwin C.M., et al. Pharmacokinetics of levetiracetam in neonates with seizures. JPediatr 2011, 159:152-154.
69. Sharpe C.M., Capparelli E.V., Mower A., Farrell M.J., Soldin S.J., Haas R.H. Aseven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res 2012, 72:43-49.
70. Shoemaker M.T., Rotenberg J.S. Levetiracetam for the treatment of neonatal seizures. JChild Neurol 2007, 22:95-98.
71. Ng Y.T., Hastriter E.V., Cardenas J.F., Khoury E.M., Chapman K.E. Intravenous levetiracetam in children with seizures: a prospective safety study. JChild Neurol 2010, 25:551-555.
72. Fürwentsches A., Bussmann C., Ramantani G., et al. Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure 2010, 19:185-189.
73. Ramantani G., Ikonomidou C., Walter B., Rating D., Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011, 15:1-7.
74. Khan O., Chang E., Cipriani C., Wright C., Crisp E., Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011, 44:265-269.
75. Abend N.S., Gutierrez-Colina A.M., Monk H.M., Dlugos D.J., Clancy R.R. Levetiracetam for treatment of neonatal seizures. JChild Neurol 2011, 26:465-470.
76. Kilicdag H., Daglioglu K., Erdogan S., et al. The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev 2012 Dec 22, [Epub ahead of print]. 10.1016/j.earlhumdev.2012.12.002.
77. Guerrini R., Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006, 7:811-823.
78. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl. 1):S3-S9.
79. Rakhade S.N., Zhou C., Aujla P.K., Fishman R., Sucher N.J., Jensen F.E. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. JNeurosci 2008, 28:7979-7990.
80. Koh S., Jensen F.E. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol 2001, 50:366-372.
81. Cha B.H., Silveira D.C., Liu X., Hu Y., Holmes G.L. Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res 2002, 51:217-232.
82. Kaminski R.M., Banerjee M., Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004, 46:1097-1104.
83. Koh S., Tibayan F.D., Simpson J.N., Jensen F.E. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 2004, 45:569-575.
84. Kudin A.P., Debska-Vielhaber G., Vielhaber S., Elger C.E., Kunz W.S. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004, 45:1478-1487.
85. Liu Y., Barks J.D., Xu G., Silverstein F.S. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke 2004, 35:1460-1465.
86. Schubert S., Brandl U., Brodhun M., Ulrich C., Spaltmann J., Fiedler N., Bauer R. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 2005, 1058:129-136.
87. Zhao Q., Hu Y., Holmes G.L. Effect of topiramate on cognitive function and activity level following neonatal seizures. Epilepsy Behav 2005, 6:529-536.
88. Yang Y., Shuaib A., Li Q., Siddiqui M.M. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998, 804:169-176.
89. Lee S.R., Kim S.P., Kim J.E. Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett 2000, 281:183-186.
90. Edmonds H.L., Jiang Y.D., Zhang P.Y., Shank R. Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration. Life Sci 2001, 69:2265-2277.
91. Follett P.L., Deng W., Dai W., et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. JNeurosci 2004, 24:4412-4420.
92. Angehagen M., Ronnback L., Hansson E., Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. JNeurochem 2005, 94:1124-1130.
93. Zona C., Ciotti M.T., Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997, 231:123-126.
94. Costa C., Martella G., Picconi B., et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against invitro ischemia. Stroke 2006, 37:1319-1326.
95. Glier C., Dzietko M., Bittigau P., Jarosz B., Korobowicz E., Ikonomidou C. Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol 2004, 187:403-409.
96. Mikaeloff Y., Rey E., Soufflet C., et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 2004, 45:1448-1452.
97. Manitpisitkul P., Shalayda K., Todd M., Wang S.S., Ness S., Ford L. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study. Epilepsia 2013, 54:156-164.
98. Filippi L., la Marca G., Fiorini P., et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009, 50:2355-2361.
99. Kriel R., Clark A., Leppik I., Marino S., Brundage R., Cloyd J. Pharmacokinetics and safety of oral and intravenous topiramate in adult volunteers. Epilepsia 2010, (American Epilepsy Society Abstract #1.285).
100. Valencia I., Fons C., Kothare S.V., et al. Efficacy and tolerability of topiramate in children younger than 2 years old. JChild Neurol 2005, 20:667-669.
101. Veggiotti P., Longaretti F., Signorini S., Cardinali S., Lanzi G. Topiramate efficacy in an infant with partial seizures refractory to conventional antiepileptic drugs. Seizure 2004, 13:241-243.
102. Ness S., Todd M.J., Wang S., Eerdekens M., Nye J.S., Ford L. Adaptive behaviour outcomes in infants treated with adjunctive topiramate. Pediatr Neurol 2012, 46:350-358.
103. Filippi L., Poggi C., la Marca G., et al. Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. JPediatr 2010, 157:361-366.
104. Lee S., Sziklas V., Andermann F., et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003, 44:339-347.
105. Szaflarski J.P., Allendorfer J.B. Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. Epilepsy Behav 2012, 24:74-80.
106. Witt J.A., Elger C.E., Helmstaedter C. Impaired verbal fluency under topiramate - evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. Eur J Neurol 2013, 20:130-137.
107. Yasuda C.L., Centeno M., Vollmar C., et al. The effect of topiramate on cognitive fMRI. Epilepsy Res 2013 Jan 17, [Epub ahead of print].
108. Rihtman T., Parush S., Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol 2012, 34:308-311.
109. Puri V., Ness S., Sattaluri S.J., et al. Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. JChild Neurol 2011, 26:1271-1283.
110. Korinthenberg R., Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. JChild Neurol 2007, 22:302-306.
111. Zou L.P., Lin Q., Qin J., Cai F.C., Liu Z.S., Mix E. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol 2008, 31:86-92. Topiramate Study Group.
112. Zhu X., Chen O., Zhang D., Jin R., Li F., Wang Y., Sun R. Aprospective study on the treatment of infantile spasms with first-line topiramate followed by low-dose ACTH. Epilepsy Res 2011, 93:149-154.
113. Kahriman M., Minecan D., Kutluay E., Selwa L., Beydoun A. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003, 44:1353-1356.
114. Perry M.S., Holt P.J., Sladky J.T. Topiramate loading for refractory status epilepticus in children. Epilepsia 2006, 47:1070-1071.
115. Novotny E., Renfroe B., Yardi N., et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010, 74:714-720.
116. Glass H.C., Poulin C., Shevell M.I. Topiramate for the treatment of neonatal seizures. Pediatr Neurol 2011, 44:439-442.
117. Filippi L., Fiorini P., Daniotti M., et al. Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI). BMC Pediatr 2012, 12:144.
118. Silverstein F.S., Jensen F.E., Inder T., Hellström-Westas L., Hirtz D., Ferriero D.M. Improving the treatment of neonatal seizures: national Institute of Neurological Disorders and Stroke workshop report. JPediatr 2008, 153:12-15.